Longevity Next

Intervention

Recombinant adjuvanted herpes zoster vaccine

Source-reviewed Last reviewed: 2026-10-15

Research Observatory

Evidence Update

Current evidence

In ZOE-70, the recombinant shingles vaccine substantially reduced shingles compared with placebo in adults aged 70 or older. The reported efficacy analysis included 13,900 evaluable participants, not necessarily everyone originally randomized. This trial measured shingles prevention; it does not demonstrate prevention of dementia or longer life.

Combining the older participants from ZOE-50 and ZOE-70 showed that the recombinant shingles vaccine reduced persistent nerve pain after shingles compared with placebo. Short-term reactions were common and occurred more often with vaccine in ZOE-70. The pooled analysis reuses trial participants and is not a third independent trial or evidence about dementia prevention.

A US medical-record study compared older adults vaccinated during the predominantly recombinant-shingles-vaccine era with matched adults vaccinated during the earlier live-vaccine era. The newer era was associated with more dementia-diagnosis-free time among those subsequently affected. Different follow-up durations, calendar-time changes and residual confounding prevent treating this as randomized proof of prevention.

What changed

ZOE-70 showed substantial protection against herpes zoster in adults aged at least 70 receiving recombinant vaccine. Pooled ZOE-50/ZOE-70 evidence supports postherpetic-neuralgia prevention while documenting common reactogenicity. A US matched-cohort comparison associated the recombinant-vaccine era with more dementia-diagnosis-free time than the live-vaccine era, not confirmed dementia prevention.

How to read these findings

The randomized studies assessed shingles and persistent nerve pain after shingles (postherpetic neuralgia, or PHN), not dementia. The pooled analysis reuses participants. The 13,900 figure describes the evaluable efficacy population, not an asserted total randomized count.

Reactogenicity means short-term reactions such as injection-site or systemic symptoms. Similar serious-event reports do not establish equivalent safety.

The dementia finding is qualitative observational context only. Differences between vaccination eras and other remaining differences can affect it. Its published numerical discrepancy is unresolved: no dementia effect estimate, confidence interval or causal prevention claim is accepted.

Accepted limitations and study details

Exact reviewed qualifications are retained below. These details do not add a new accepted claim.

Study interpretation and limitations
  • Denominator is 13900 evaluable, not asserted as all randomized; no dementia/longevity endpoint.
  • Design: Randomized placebo-controlled vaccine trial, plus pooled ZOE-50/ZOE-70 older subgroup
  • Safety: Solicited injection-site/systemic reactions 79.0% versus 29.5%; serious events/deaths broadly similar, not equivalent.
  • Interpretation: 13900 evaluable is not necessarily randomized total; PHN pool reuses ZOE-70.
  • Pooling reuses ZOE-70 participants; do not count this as an independent third vaccine trial or dementia evidence.
  • This was an observational comparison of vaccination eras, not a randomized dementia-prevention trial.
  • Calendar-time differences, residual confounding, unequal follow-up, dementia ascertainment and competing mortality limit interpretation.
  • A discrepancy between the paper's text and table remains unresolved; no numerical effect or confidence interval is presented.
  • Observational vaccine-era association with residual/calendar-time confounding and unequal follow-up; no established dementia prevention.
  • Published interval discrepancy remains unresolved.
  • No numerical effect or interval accepted.

Why it matters

These findings apply to the studied populations, regimens and outcomes; they do not establish generalized longevity benefit.

Next proof

Longer protection durability and population-specific safety evidence. Long-term PHN and harms estimates with exact risk-group denominators. Independent randomized dementia outcomes and reconciliation of reported interval variants.

Evidence reviewed through

Evidence release LNPG-REL-20261015-001

Sources

Randomized shingles / pooled neuralgia evidence

  1. Original randomized trial report

    Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

    Publication date 2016-09-15

    Outcome assessed Confirmed herpes zoster; modified/evaluable trial population Postherpetic neuralgia in pooled >=70 group; solicited reactions

    Important limitation Denominator is 13900 evaluable, not asserted as all randomized; no dementia/longevity endpoint. Pooling reuses ZOE-70 participants; do not count this as an independent third vaccine trial or dementia evidence.

    Evidence access Public author abstract and bibliographic metadata reviewed; full methods/tables were not reviewed.

Observational dementia context — qualitative only

  1. Observational study — context only

    The recombinant shingles vaccine is associated with lower risk of dementia.

    Publication date 2024

    Outcome assessed Restricted mean time lost over six years, diagnosis-free time among affected people

    Important limitation Observational vaccine-era association with residual/calendar-time confounding and unequal follow-up; no established dementia prevention. Published interval discrepancy remains unresolved. No numerical effect or interval accepted.

    Evidence access Public primary-repository Results Par5 and Table 1 freshly compared (PMC11485228); discrepancy confirmed, not adjudicated. No confidence interval promoted.

Opens in a new tab